Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Jul-Aug;37(4):1735-1742.
doi: 10.21873/invivo.13261.

Prognostic Significance of Immune-checkpoint Molecule PD-L1 in Classical Hodgkin Lymphoma: A Clinicopathologic Study of 120 Cases

Vaclav Kubes  1 , Leos Kren  1 , Filip Sokol  1 , Jozef Michalka  2 , Jan Muzik  3 , Tomas Arpas  2 , Zdenka Krenova  4 , Zdenek Kral  5
Affiliations

Prognostic Significance of Immune-checkpoint Molecule PD-L1 in Classical Hodgkin Lymphoma: A Clinicopathologic Study of 120 Cases

Vaclav Kubes et al. In Vivo. 2023 Jul-Aug.

Abstract

Background/aim: Classic Hodgkin lymphoma (cHL) is a common B-cell malignancy. Despite the good prognosis, in some patients the standard chemotherapy and radiotherapy-based approach does not lead to long-term remission, and these patients eventually relapse. Moreover, the primary refractory disease is of major concern regarding prognosis.

Patients and methods: We performed a retrospective analysis to evaluate PD-L1 expression in 120 patients with classic Hodgkin lymphoma (cHL).

Results: The median follow-up of the entire group of patients was 90 months. After initial therapy, complete remission was achieved in 113 (94.2%) patients. During the follow-up, cHL relapse/refractory disease was reported in 23 (19.2%) cases. A total of five patients died during the follow-up period, all from cHL progression. When determining PD-L1 expression on Hodgkin-Reed-Sternberg (HRS) cells, 37 cases (30.8%) were evaluated as negative, and 83 cases (69.2%) as positive. In the negative PD-L1 group of patients, no cHL relapse/refractory disease was observed during the follow-up period. However, out of 83 patients with positive PD-L1 expression on HRS cells, 23 (28%) showed relapse/refractory cHL.

Conclusion: A significantly higher relapse rate was observed in PD-L1-positive patients diagnosed with cHL.

Keywords: Classic Hodgkin lymphoma; PD-L1 expression; overall survival; relapse; treatment.

PubMed Disclaimer

Conflict of interest statement

The Authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Figures

Figure 1
Figure 1. Relapse-free survival of classic Hodgkin lymphoma patients according to PD-L1 positivity in Hodgkin-Reed-Sternberg cells.
Figure 2
Figure 2. Relationship of PD-L1 positivity in background cells and stage of the disease (p<0.032).
See this image and copyright information in PMC

References

    1. Glaser S, Jarrett R. 1 The epidemiology of Hodgkin’s disease. Baillière’s Clinical Haematology. 2020;9(3):401–416. doi: 10.1016/S0950-3536(96)80018-7. - DOI - PubMed
    1. Rozalli F, Chua S, Green D. Elucidation of acute renal failure due to recurrent non-Hodgkin lymphoma by F-18 FDG PET/CT. Clinical Nuclear Medicine. 2021;33(3):201–203. doi: 10.1097/RLU.0b013e318162ddc7. - DOI - PubMed
    1. Ansell S. Hodgkin lymphoma: 2018 update on diagnosis, risk-stratification, and management. American Journal of Hematology. 2021;93(5):704–715. doi: 10.1002/ajh.25071. - DOI - PubMed
    1. Longo D, Duffey P, Young R, Hubbard S, Ihde D, Glatstein E, Phares J, Jaffe E, Urba W, Devita V. Conventional-dose salvage combination chemotherapy in patients relapsing with Hodgkin’s disease after combination chemotherapy: the low probability for cure. Journal of Clinical Oncology. 2022;10(2):210–218. doi: 10.1200/JCO.1992.10.2.210. - DOI - PubMed
    1. Master S, Koshy N, Wilkinson B, Rosen K, Mills G, Mansour R, Shi R. Effect of radiation therapy on survival in Hodgkin’s lymphoma: A SEER data analysis. Anticancer Res. 2017;37:3035–3043. doi: 10.21873/anticanres.11658. - DOI - PubMed